Compare Beyond Meat Inc (BYND) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Citius Pharmaceuticals Inc — how do they compare? Beyond Meat Inc trades at $0.4 (market cap $215.41M), while Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M). The key difference: Beyond Meat Inc is far larger — about 10.8× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| BYND | CTXR | |
|---|---|---|
Market Cap | $215.41M | $20.01M |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $1.82 |
52-Week Low | $0.42 | $0.48 |
Enterprise Value | $455.69M | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYND trades at $0.40, down 22.6% amid a 30:1 reverse stock split announced August 14, 2026. Despite beating Q2 2026 EPS estimates, revenue has declined from $419M in 2022 to $275M in 2025. The stock shows bearish technical signals with oversold RSI readings. Analyst consensus is heavily bearish with 57% sell ratings, reflecting concerns over cash burn and market positioning.
The outlook remains challenging with declining revenues and negative operating cash flow. Investment opportunity exists if turnaround efforts succeed in international markets, but risks include persistent cash burn, competitive pressures, and execution uncertainty. The reverse split addresses listing requirements but doesn't resolve fundamental business challenges.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
